Effect of glatiramer acetate in patients with primary progressive Multiple Sclerosis

Trial Profile

Effect of glatiramer acetate in patients with primary progressive Multiple Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PROMiSe
  • Most Recent Events

    • 28 Apr 2017 Results of reanalysis of PROMiSe trial dataset assessing characteristics and confirmed disability progression (CDP) rates of patients according to cerebrospinal fluid (CSF) status, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top